Monday, November 9, 2020 – Pfizer together with BioNTech announce the efficacy of the ‘in-the-works’ Covid-19 vaccine as 90% effective. The vaccine is in its 3rd Phase of the trial.
“The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19,” Pfizer chairman and CEO Albert Bourla said in a statement.
“We are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis,” he said.
“We are reaching this critical milestone in our vaccine development program at a time when the world needs it most.”
Dow (INDU) stocks skyrocketed to 1,600 points in the early hours of the Monday trade in response to the positive outcome of the vaccine.